Back to Archived Journals » International Journal of High Throughput Screening » Volume 1
An overview of urinary proteomics applications in human diseases
Authors Gopalan G, Rao V, Kakkar VV
Published 18 November 2010 Volume 2010:1 Pages 183—192
DOI https://doi.org/10.2147/IJHTS.S13129
Review by Single anonymous peer review
Peer reviewer comments 3
Gayathri Gopalan1, Veena S Rao1, Vijay V Kakkar2
1Tata Proteomics and Coagulation Unit, Thrombosis Research Institute, Bangalore, India; 2Thrombosis Research Institute, London, United Kingdom
Abstract: A major challenge in clinical proteomics is the identification of reliable biomarkers that help early diagnosis of disease, which will not only assist the clinician but also contribute to the development of personalized medicine. Urinary proteomic studies provide information on urine composition along with insight into renal physiology, kidney disease states, and other associated diseases. In the past decade, technical advances in the design of highly sensitive mass spectrometers and accurate protein quantitation technologies have led to the application of urinary proteomics in diverse research areas, including basic biomedical and clinical sciences. Of specific interest is the identification of biomarkers by virtue of improvements in instrumentation, bioinformatics, and database development. Here, we review recent discoveries in urinary proteomics with respect to identifying novel biomarker, its current challenges, and potential for future research.
Keywords: urinary proteomics, biomarker, mass spectrometry
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.